Lantern Financial Statements From 2010 to 2024

LTRN Stock  USD 3.08  0.13  4.41%   
Lantern Pharma financial statements provide useful quarterly and yearly information to potential Lantern Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lantern Pharma financial statements helps investors assess Lantern Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lantern Pharma's valuation are summarized below:
Market Capitalization
33.2 M
Earnings Share
(1.78)
We have found one hundred twenty available fundamental ratios for Lantern Pharma, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lantern Pharma's last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 23rd of November 2024, Market Cap is likely to grow to about 92.6 M, while Enterprise Value is likely to drop about 23.5 M.
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.9 K, Interest Expense of 246.8 K or Selling General Administrative of 4.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.19. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
  
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Lantern Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.4 M43.6 M15.9 M
Slightly volatile
Other Current Liabilities1.3 M2.5 M905.4 K
Slightly volatile
Total Current Liabilities1.7 M2.7 M1.1 M
Slightly volatile
Property Plant And Equipment Net294.4 K280.4 K63.9 K
Slightly volatile
Accounts Payable2.6 M2.5 M570 K
Slightly volatile
Cash24.1 M21.9 M10.6 M
Slightly volatile
Non Current Assets Total363.2 K306.3 K158.8 K
Slightly volatile
Non Currrent Assets Other47.8 K25.9 K29.6 K
Slightly volatile
Cash And Short Term Investments34.5 M41.3 M15.1 M
Slightly volatile
Common Stock Total Equity9299777.9 K
Slightly volatile
Common Stock Shares Outstanding9.4 M10.8 M7.4 M
Slightly volatile
Liabilities And Stockholders Equity36.4 M43.6 M15.9 M
Slightly volatile
Capital Surpluse115.5 M110 M32.9 M
Slightly volatile
Other Stockholder Equity61 M96.3 M28.4 M
Slightly volatile
Total Liabilities1.8 M2.7 M1.1 M
Slightly volatile
Total Current Assets36.1 M43.3 M15.8 M
Slightly volatile
Capital StockK1.1 K13.3 K
Slightly volatile
Common StockK1.1 K7.9 K
Slightly volatile
Property Plant Equipment65.8 K55.2 K30.5 K
Slightly volatile
Other Assets19.5 K20.6 K205.8 K
Very volatile
Other Current Assets1.6 MM602.7 K
Slightly volatile
Deferred Long Term Liabilities116.9 K91.1 K161.4 K
Slightly volatile
Property Plant And Equipment Gross294.4 K280.4 K66.4 K
Slightly volatile
Short and Long Term Debt Total165.2 K234.5 K123.4 K
Slightly volatile
Long Term Debt86.8 K97.7 K106.3 K
Slightly volatile
Non Current Liabilities Other86.8 K97.7 K106.3 K
Slightly volatile
Net Receivables598.8 K860 K281.5 K
Slightly volatile
Short Term Debt138.6 K173 K145.9 K
Pretty Stable

Lantern Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.2 MM2.4 M
Slightly volatile
Other Operating Expenses10.1 M17.9 M5.3 M
Slightly volatile
Research Development12.5 M11.9 M3.3 M
Slightly volatile
Total Operating Expenses10.1 M17.9 M5.3 M
Slightly volatile
Cost Of Revenue95 K174.8 K36.1 K
Slightly volatile
Non Recurring1.8 MM2.2 M
Slightly volatile
Selling And Marketing Expenses4.8 B5.4 B5.9 B
Slightly volatile

Lantern Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings86.8 K97.7 K106.3 K
Slightly volatile
Stock Based Compensation863.9 K1.1 M470.7 K
Slightly volatile
Begin Period Cash Flow20.6 M37.7 M9.5 M
Slightly volatile
Capital Expenditures16.4 K18.7 K10.1 K
Slightly volatile
End Period Cash Flow24.4 M21.9 M10.7 M
Slightly volatile
Change To Netincome2.1 MM665.6 K
Slightly volatile
Change To Liabilities607.8 K667.4 K306.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables322.5 K419.6 K334 K
Slightly volatile
Capex To Depreciation0.10.10713.0109
Slightly volatile
Cash Per Share2.53.80941.4543
Slightly volatile
Income Quality0.70.89880.7875
Slightly volatile
Net Debt To EBITDA1.621.37481.0545
Slightly volatile
Current Ratio14.4316.18318.5443
Slightly volatile
Graham Number6.1611.17913.73
Slightly volatile
Debt To Equity0.00440.0050.0054
Slightly volatile
Capex Per Share0.00150.00170.0013
Slightly volatile
Interest Debt Per Share0.01450.0170.0174
Pretty Stable
Debt To Assets0.00430.00480.0052
Slightly volatile
Ebt Per Ebit1.050.89280.9809
Very volatile
Long Term Debt To Capitalization0.00440.00490.0054
Slightly volatile
Total Debt To Capitalization0.00440.00490.0054
Slightly volatile
Debt Equity Ratio0.00440.0050.0054
Slightly volatile
Quick Ratio14.4716.18318.5663
Slightly volatile
Net Income Per E B T1.091.141.0101
Slightly volatile
Cash Ratio10.898.19136.5337
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00131.009
Slightly volatile
Debt Ratio0.00430.00480.0052
Slightly volatile

Lantern Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap92.6 M46.4 M89.4 M
Slightly volatile
Enterprise Value23.5 M24.7 M75.9 M
Slightly volatile

Lantern Fundamental Market Drivers

Cash And Short Term Investments41.3 M

Lantern Upcoming Events

18th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
18th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lantern Pharma Financial Statements

Lantern Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how Lantern Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.5 B-2.4 B
Cost Of Revenue174.8 K95 K

Pair Trading with Lantern Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lantern Stock

  0.69ME 23Andme HoldingPairCorr
  0.68VALN Valneva SE ADRPairCorr

Moving against Lantern Stock

  0.49KZR Kezar Life SciencesPairCorr
  0.41MLYS Mineralys Therapeutics,PairCorr
  0.4NXGLW NexGel WarrantPairCorr
The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.
The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.78)
Return On Assets
(0.28)
Return On Equity
(0.45)
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.